search
Back to results

Evaluation of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp in Moderate to Severe Chronic Periodontitis

Primary Purpose

Moderate to Severe Chronic Periodontitis

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
KLOX BioPhotonic OraLum Gel
Scaling and Root Planing (SRP)
Sponsored by
KLOX Technologies Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Moderate to Severe Chronic Periodontitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Signed and dated written informed consent form;
  2. Male or female patients aged 18 years old and above;
  3. Good general health, free of systemic diseases such as diabetes, arthritis, HIV infection or genetic disorder that could influence the outcome of the treatment;
  4. Patient with clinically confirmed signs and symptoms of generalized moderate to severe chronic periodontitis (as defined according to International Classification of Periodontal Diseases, Armitage 1999);
  5. Patient has had no periodontal treatment for the last year prior to the study;
  6. Females of childbearing potential must not be pregnant nor lactating at study entry and agree to use an adequate contraceptive method during the study.

    Inclusion Criteria Post Oral Hygiene Instructions (OHI):

  7. Patient demonstrates sufficient plaque control as indicated by a plaque score < 30% after hygiene period;
  8. Patient has at least two sites in each quadrant with probing pocket depth (PPD) equal or more than 5 mm or equal or less than 7 mm.

Exclusion Criteria:

  1. Patient with an existing aggressive periodontitis;
  2. Presence of oral local mechanical factor(s) that could, in the opinion of the investigator, influence the outcome of the study;
  3. Presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed;
  4. Soft or hard tissue tumours of the oral cavity;
  5. Systemic antibiotic therapy or anti-inflammatory drugs or any other medication(s) that might interfere with periodontal healing within the last three months prior to study entry and throughout the study duration;
  6. Patient has participated in any other clinical study within 30 days prior to study entry and throughout the study duration;
  7. Use of anticoagulants such as warfarin, clopidogrel, enoxaparin or high doses of aspirin (162 mg daily);
  8. Regular use of chlorhexidine oral rinses / mouthwashes (Non-medicated, over the counter, mouthwashes are acceptable);
  9. Patient with current alcohol abuse or actively consuming drugs (addiction); as it may interfere with patient's ability to comply with study procedures
  10. Periodontal surgery planned during the study;
  11. Female patient pregnant, nursing or planning to become pregnant within the next 12 months;
  12. Patient is a current smoker or had been smoking or using nicotine product(s) in the last six months;
  13. Concurrent disease (such as porphyria) or drug(s) (such as methotrexate or chloroquine) known to induce severe photosensitivity of the skin;
  14. Patient has ongoing malignant disease of any type, or any significant chronic disease which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or would result in non-compliance with the study protocol;
  15. Patients with known hypersensitivity to peroxide;
  16. Patients with known photosensitivity or who take drugs to treat photosensitivity.

Sites / Locations

  • Dr. Anthony Seminara Inc.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

KLOX BioPhotonic OraLum Gel + SRP

Scaling and Root Planing (SRP)

Arm Description

Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.

The second half-mouth will be treated with SRP alone.

Outcomes

Primary Outcome Measures

Adverse events, Serious adverse events and incidents
Number of patients with adverse events, serious adverse events and incidents
Ease of performing SRP and time required to perform SRP

Secondary Outcome Measures

Impact on tissues (Visual examination of tissues)
Visual examination of tissues
Impact on bleeding (Use of Bleeding on Probing (BOP) results)
Use of Bleeding on Probing (BOP) results
Impact on Plaque Index (PI)
Impact on Gingival index (GI)
Pain (Visual Analog Scale)

Full Information

First Posted
December 17, 2014
Last Updated
February 22, 2016
Sponsor
KLOX Technologies Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02325570
Brief Title
Evaluation of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp in Moderate to Severe Chronic Periodontitis
Official Title
The Evaluation of the Clinical Effects of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp as an Adjunct to the Non-Surgical Treatment of Moderate to Severe Chronic Periodontitis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
November 2014 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
May 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
KLOX Technologies Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Multicenter, prospective, interventional open case series study using a randomized split-mouth design in moderate to severe chronic periodontitis patients having half-mouth treated with the KLOX BioPhotonic OraLum gel with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP) versus SRP alone in the second (control) half-mouth.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Moderate to Severe Chronic Periodontitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
KLOX BioPhotonic OraLum Gel + SRP
Arm Type
Experimental
Arm Description
Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.
Arm Title
Scaling and Root Planing (SRP)
Arm Type
Other
Arm Description
The second half-mouth will be treated with SRP alone.
Intervention Type
Device
Intervention Name(s)
KLOX BioPhotonic OraLum Gel
Intervention Description
Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
Intervention Type
Procedure
Intervention Name(s)
Scaling and Root Planing (SRP)
Intervention Description
Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
Primary Outcome Measure Information:
Title
Adverse events, Serious adverse events and incidents
Description
Number of patients with adverse events, serious adverse events and incidents
Time Frame
3 weeks
Title
Ease of performing SRP and time required to perform SRP
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Impact on tissues (Visual examination of tissues)
Description
Visual examination of tissues
Time Frame
3 weeks
Title
Impact on bleeding (Use of Bleeding on Probing (BOP) results)
Description
Use of Bleeding on Probing (BOP) results
Time Frame
2 weeks
Title
Impact on Plaque Index (PI)
Time Frame
2 weeks
Title
Impact on Gingival index (GI)
Time Frame
2 weeks
Title
Pain (Visual Analog Scale)
Time Frame
2 weeks
Other Pre-specified Outcome Measures:
Title
Exploratory endpoint: patient's preference questionnaire
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed and dated written informed consent form; Male or female patients aged 18 years old and above; Good general health, free of systemic diseases such as diabetes, arthritis, HIV infection or genetic disorder that could influence the outcome of the treatment; Patient with clinically confirmed signs and symptoms of generalized moderate to severe chronic periodontitis (as defined according to International Classification of Periodontal Diseases, Armitage 1999); Patient has had no periodontal treatment for the last year prior to the study; Females of childbearing potential must not be pregnant nor lactating at study entry and agree to use an adequate contraceptive method during the study. Inclusion Criteria Post Oral Hygiene Instructions (OHI): Patient demonstrates sufficient plaque control as indicated by a plaque score < 30% after hygiene period; Patient has at least two sites in each quadrant with probing pocket depth (PPD) equal or more than 5 mm or equal or less than 7 mm. Exclusion Criteria: Patient with an existing aggressive periodontitis; Presence of oral local mechanical factor(s) that could, in the opinion of the investigator, influence the outcome of the study; Presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed; Soft or hard tissue tumours of the oral cavity; Systemic antibiotic therapy or anti-inflammatory drugs or any other medication(s) that might interfere with periodontal healing within the last three months prior to study entry and throughout the study duration; Patient has participated in any other clinical study within 30 days prior to study entry and throughout the study duration; Use of anticoagulants such as warfarin, clopidogrel, enoxaparin or high doses of aspirin (162 mg daily); Regular use of chlorhexidine oral rinses / mouthwashes (Non-medicated, over the counter, mouthwashes are acceptable); Patient with current alcohol abuse or actively consuming drugs (addiction); as it may interfere with patient's ability to comply with study procedures Periodontal surgery planned during the study; Female patient pregnant, nursing or planning to become pregnant within the next 12 months; Patient is a current smoker or had been smoking or using nicotine product(s) in the last six months; Concurrent disease (such as porphyria) or drug(s) (such as methotrexate or chloroquine) known to induce severe photosensitivity of the skin; Patient has ongoing malignant disease of any type, or any significant chronic disease which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or would result in non-compliance with the study protocol; Patients with known hypersensitivity to peroxide; Patients with known photosensitivity or who take drugs to treat photosensitivity.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony Seminara, DDM
Organizational Affiliation
Dr. Anthony Seminara Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dr. Anthony Seminara Inc.
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4X 2E9
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp in Moderate to Severe Chronic Periodontitis

We'll reach out to this number within 24 hrs